June 22, 2018—Beckman Coulter announced the results of a clinical trial suggesting that blood tests may offer benefits in the initial screening for obstructive sleep apnea. The study, which involved 264 male adult patients from six institutions, revealed that screening for changes in three specific biomarkers–hemoglobin A1c, C-reactive protein, and erythropoietin–may be useful in helping identify obstructive sleep apnea. The results of the pivotal study were published in Nature and Science of Sleep (Fleming WE, et al. 2018;10:159–167). Beckman Coulter offers HbA1c and CRP tests on its Synchron and AU chemistry systems and EPO on the DxI and Access 2 immunoassay systems.
“The study results demonstrate that sleep apnea induces a characteristic signature cluster of blood biomarker changes,” Wesley Elon Fleming, MD, of Sleep Center Orange County, said in a release from Beckman. “Concurrent elevations of HbA1c, CRP, and EPO levels should generate a high index of suspicion of obstructive sleep apnea, and thus, may be useful as an initial screening tool in adult males.” Dr. Fleming is also a diplomate of the American Board of Sleep Medicine and principal investigator and lead author of the study.
Patients with sleep apnea are at increased risk for cardiovascular disease, diabetes, and other chronic conditions. The disorder affects an estimated 100 million adults worldwide.